acrolein has been researched along with diclofenac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boa, AN; Chandrabalan, A; McPhillie, MJ; Morice, AH; Sadofsky, LR | 1 |
| Johansson, J; Lahti, A | 1 |
| Cao, D; Cao, Z; Chen, X; Huang, D; Huang, H; Wang, Y; Wang, Z; Zhang, X; Zhou, B | 1 |
3 other study(ies) available for acrolein and diclofenac
| Article | Year |
|---|---|
N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
Topics: Animals; Calcium Signaling; Cinnamates; Guinea Pigs; HEK293 Cells; Humans; Male; Molecular Docking Simulation; ortho-Aminobenzoates; Structure-Activity Relationship; TRPA1 Cation Channel | 2019 |
Topical non-steroidal anti-inflammatory drugs inhibit non-immunologic immediate contact reactions.
Topics: Acrolein; Adult; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Benzoic Acid; Dermatitis, Contact; Diclofenac; Dimethyl Sulfoxide; Female; Humans; Irritants; Male; Naproxen; Nicotinic Acids; Regional Blood Flow; Salicylates; Skin | 1988 |
Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Topics: Acrolein; Aldehyde Reductase; Aldo-Keto Reductases; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diclofenac; DNA Damage; Humans; Lung Neoplasms; Phthalazines | 2014 |